hn.today

Pill to treat pancreatic cancer hailed as 'biggest breakthrough in decades'

theguardian.com1130 points240 comments
Screenshot of Pill to treat pancreatic cancer hailed as 'biggest breakthrough in decades'

Daraxonrasib, an oral drug that blocks cancer-driving KRAS mutations, produced unusually strong results in a trial involving 61 people with recently diagnosed pancreatic cancer that had spread to other organs. After an average of 18 months of follow-up, tumours had stopped growing in 90% of participants, and had shrunk or disappeared in just over 60%. In about 8% - roughly one patient in 12 - the cancer was no longer detectable on CT scans. A year after treatment began, 76.6% of participants were alive, compared with the usual 40-45% survival at one year for patients receiving chemotherapy alone.

The findings are notable because advanced pancreatic cancer has a grim outlook: about half of those diagnosed die within three months, and only around 3% survive five years when the disease has spread. Doctors say the drug is not yet a cure, and it is unknown how long it can control the cancer; longer studies will assess whether the deep responses last or become remissions. Researchers describe the results as a major advance and suggest KRAS-blocking drugs may also help against other cancers with similar mutations. More trials are needed before daraxonrasib can be considered for routine treatment, and the gains do not change the disease’s overall poor survival prospects.

Read on theguardian.com240 comments on Hacker News

Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.

More in Science

The daily digest

Today's best Hacker News stories, summarized and screenshotted, one email a day.